Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Change in Cash (2016 - 2025)

Historic Change in Cash for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $13.0 million.

  • Celldex Therapeutics' Change in Cash rose 30493.69% to $13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$362000.0, marking a year-over-year decrease of 10237.14%. This contributed to the annual value of -$6.5 million for FY2024, which is 21992.57% down from last year.
  • As of Q3 2025, Celldex Therapeutics' Change in Cash stood at $13.0 million, which was up 30493.69% from $5.9 million recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' Change in Cash registered a high of $80.3 million during Q1 2024, and its lowest value of -$72.3 million during Q2 2024.
  • Its 5-year average for Change in Cash is -$410473.7, with a median of -$6.3 million in 2024.
  • In the last 5 years, Celldex Therapeutics' Change in Cash plummeted by 93330.12% in 2023 and then surged by 30493.69% in 2025.
  • Over the past 5 years, Celldex Therapeutics' Change in Cash (Quarter) stood at -$33.0 million in 2021, then skyrocketed by 132.83% to $10.8 million in 2022, then rose by 26.13% to $13.7 million in 2023, then plummeted by 158.79% to -$8.0 million in 2024, then surged by 261.54% to $13.0 million in 2025.
  • Its Change in Cash stands at $13.0 million for Q3 2025, versus $5.9 million for Q2 2025 and -$11.2 million for Q1 2025.